Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Cezary Swider"'
Autor:
John P. Dowling, Pavel A. Nikitin, Fang Shen, Halley Shukla, James P. Finn, Nirja Patel, Cezary Swider, Jamie L. Bingaman-Steele, Chris Nicolescu, Eden L Sikorski, Evan J. Greenawalt, Michael J. Morin, Matthew K. Robinson, Karen Lundgren, Benjamin C. Harman
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTImmune checkpoint inhibitors that overcome T cell suppressive mechanisms in tumors have revolutionized the treatment of cancer but are only efficacious in a small subset of patients. Targeting suppressive mechanisms acting on innate immune ce
Externí odkaz:
https://doaj.org/article/687ffc074dce4fcdb4a25e4af9665e76
Autor:
Martin Carroll, Anthony R. Mato, Adam Bagg, Cezary Swider, James E. Thompson, Steven C. Goldstein, Edward A. Stadtmauer, David L. Porter, Stephen J. Schuster, Alexander E. Perl, Alison W. Loren, Ami Goradia, Melissa Potuzak, Allison Kemner, Dan T. Vogl, Charalambos Andreadis, Selina M. Luger, Donald E. Tsai
Purpose: Bexarotene is a retinoic X receptor agonist that has been shown in vitro to inhibit growth and induce differentiation of myeloid leukemic cell lines. We therefore conducted a phase I dose escalation study to assess the maximum tolerated dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72980f111e3a7e34bdee6917313897a9
https://doi.org/10.1158/1078-0432.c.6517141.v1
https://doi.org/10.1158/1078-0432.c.6517141.v1
Autor:
Martin Carroll, Anthony R. Mato, Adam Bagg, Cezary Swider, James E. Thompson, Steven C. Goldstein, Edward A. Stadtmauer, David L. Porter, Stephen J. Schuster, Alexander E. Perl, Alison W. Loren, Ami Goradia, Melissa Potuzak, Allison Kemner, Dan T. Vogl, Charalambos Andreadis, Selina M. Luger, Donald E. Tsai
CCR Translation on this Article from A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da4499a30d60647454a80a5eddc11759
https://doi.org/10.1158/1078-0432.22439710.v1
https://doi.org/10.1158/1078-0432.22439710.v1
Autor:
John Dowling, Pavel Nikitin, Cezary Swider, Chris Nicolescu, Halley Shukla, Jamie Bingaman-Steele, Nirja Patel, Eden Sikorski, Benjamin Harman, Jillian DiMuzio, Karen Lundgren, Yumi Ohtani, Michael Morin, Matthew Robinson, Fang Shen
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fea737a0bf0bd9419649e65c36ecccf
https://doi.org/10.1136/jitc-2022-sitc2022.0823
https://doi.org/10.1136/jitc-2022-sitc2022.0823
Autor:
John P Dowling, Pavel A Nikitin, Fang Shen, James P Finn, Nirja Patel, Cezary Swider, Jamie Steele, Halley Shukla, Matthew K Robinson, Karen Lundgren, Benjamin C Harman
Publikováno v:
Molecular Cancer Therapeutics. 20:LBA022-LBA022
Immune checkpoint inhibitors that overcome T cell suppressive mechanisms in tumors have revolutionized the treatment of cancer. However, therapies targeting innate immune cell subsets that orchestrate adaptive immune responses could significantly imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50521b0d8fffba8fe695268fd3568269
https://doi.org/10.1158/1535-7163.targ-21-lba022
https://doi.org/10.1158/1535-7163.targ-21-lba022
Autor:
Donald E. Tsai, Melissa Potuzak, Alison W. Loren, Ami Goradia, James E. Thompson, Stephen J. Schuster, Cezary Swider, Selina M. Luger, Edward A. Stadtmauer, Dan T. Vogl, Alexander E. Perl, David L. Porter, Charalambos Andreadis, Allison Kemner, Martin Carroll, Anthony R. Mato, Adam Bagg, Steven C. Goldstein
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(17)
Purpose: Bexarotene is a retinoic X receptor agonist that has been shown in vitro to inhibit growth and induce differentiation of myeloid leukemic cell lines. We therefore conducted a phase I dose escalation study to assess the maximum tolerated dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f91743fbbdc4efbbc5ae5afcebd53f2e
https://pubmed.ncbi.nlm.nih.gov/18765520
https://pubmed.ncbi.nlm.nih.gov/18765520
Autor:
Cezary Swider, Edward A. Stadtmauer, Adam Bagg, Richard G. Ghalie, Selina M. Luger, David L. Porter, Donald E. Tsai, Allison Kemner, James E. Thompson, Steven A. Goldstein, Ewa Tomczak, Martin Carroll, Alexander E. Perl, Stephen J. Schuster, Charlambos Andreadis, Ami Goradia, Alison W. Loren, Doris DiPatri, Peter C. Nowell
Publikováno v:
Cancer biologytherapy. 6(1)
All-trans-retinoic acid has dramatically changed the treatment paradigm for acute promyelocytic leukemia, however, it has no significant activity in non-M3 acute myeloid leukemia (AML). In vitro, bexarotene, a retinoid X receptor agonist inhibits the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a88cd419f2e12150ff2c7c3d409e41fb
https://pubmed.ncbi.nlm.nih.gov/17204865
https://pubmed.ncbi.nlm.nih.gov/17204865
Autor:
David Krag, David S. Knight, Scott K. Dessain, Hossein Borghaei, Paul Simon, Michael G. Walker, R. Katherine Alpaugh, Tung Chan, Huiwu Zhao, Baron Christopher Heimbach, Cezary Swider
Publikováno v:
Cancer Research. 75:1277-1277
Introduction: Cancer cells express novel antigens that reflect their transformed state and may engender an antibody response. We hypothesize that some of these auto-antibodies detect neo-antigens that are shared by diverse tumor types and that a subs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e2973de30816afa7c061c58b31e80ff
https://doi.org/10.1158/1538-7445.am2015-1277
https://doi.org/10.1158/1538-7445.am2015-1277
Autor:
Huiwu Zhao, Scott K. Dessain, Hossein Borghaei, Cezary Swider, Baron Christopher Heimbach, Paul Simon, Maureen E. Murphy, Jiping Zhang, Sharad P. Adekar, Ramdev Puligedda
Publikováno v:
Cancer Research. 74:3625-3625
Introduction: New cancer-specific antigens are needed to fully realize the potential of antibody-based cancer therapies. Cancer cells express novel antigens that are characteristic of the transformed state and may engender an antibody response in pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51035571001336d8fc9a4cebafa1b78f
https://doi.org/10.1158/1538-7445.am2014-3625
https://doi.org/10.1158/1538-7445.am2014-3625
Autor:
Selina M. Luger, Alexander E. Perl, Cezary Swider, Anthony R. Mato, Emile Youssef, Donald E. Tsai, Melissa Potuzak, Adam Bagg, David L. Porter, Edward A. Stadtmauer, Alison W. Loren, Steven A. Goldstein
Publikováno v:
Blood. 112:4040-4040
In vitro, bexarotene inhibits the proliferation of non-M3 AML cell lines and induces differentiation of leukemic blasts. Our previous phase I study in non-M3 AML showed evidence of leukemic response as manifested by reduction in bone marrow blast cou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfcf64c29a74028e5343b6427348439e
https://doi.org/10.1182/blood.v112.11.4040.4040
https://doi.org/10.1182/blood.v112.11.4040.4040